在心脏性休克中控制心律失常:对米利诺和多布塔明治疗的洞察力
Jodi-Ann A Fletcher1, Savitri Poornima Halaharvi2, Cinda Manuvel3
1Internal Medicine, St. George's University School of Medicine, St. George, GRD.
Cureus
|January 21, 2025
概括
本综述检查了心脏发生性休克 (CS) 中的米利诺和多布他胺引起的心律失常. 虽然dobutamine缩短了住院时间,但它增加了由于心律失常的死亡率,与milrinone不同.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏性休克 (CS) 损害了重要器官的输液,并可能导致心律失常.
- 米利诺和多布他胺是用于CS的内类药物,具有不同的作用机制和潜在的不良影响.
研究的目的:
- 在CS患者中审查米利诺和多布塔明诱导的心律失常的治疗策略.
- 为了比较milrinone和dobutamine在管理CS中的疗效和安全性,重点关注心律失常的潜力.
主要方法:
- 从PubMed,谷歌学者和科克兰图书馆的文献进行叙事审查.
- 专注于研究CS中的milrinone和dobutamine及其相关心律失常的研究.
主要成果:
- 有限的证据有利于一种异型药物比另一种更好地用于CS管理.
- 多布他胺使用与更短的住院时间有关,但由于心律失常导致的全因死亡率增加.
- 这两种药物都诱导了心室和心室上动脉节律失常症; 埃斯莫洛尔在减轻多布他的作用方面表现出有效性.
结论:
- 量身定制的方法对于管理CS中阳性性心律失常至关重要.
- 临床警和个性化患者护理在使用多布他或米利诺时至关重要.
相关概念视频
Heart Failure Drugs: Inotropic Agents
510
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
510
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
706
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
706
Disturbances in Heart Rhythm
889
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
889
Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Mechanism of Cardiac Arrhythmias
885
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
885


